IL0011224156
© PR Newswire
28.01.2026
ICCM
LISTED
NASDAQ
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
News Preview
ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" is pending finalization following the end of its open comment period on January 23, 2026Inclusion of cryoablation in medical society guidelines is expected to result in more breast surgeons recommen...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
ICCM
LISTED
NASDAQ
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
News Preview
Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patientsRecord European sales, driven by positive effects of U.S. clearance and continued grow...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2025
ICCM
LISTED
NASDAQ
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
News Preview
ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United StatesCAESAREA, Israel, Dec. 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation t...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
10.12.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
News Preview
Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense®CAESAREA, Israel, Dec. 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablati...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
05.12.2025
ICCM
LISTED
NASDAQ
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
News Preview
Cryogenic flow control enhances the efficacy and precision of cryoablation proceduresRobust IP portfolio becomes increasingly strategic as global interest in IceCure's platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization in low-risk breast cancerCAESAREA, Israel, Dec. 5, 2025 /PRNew...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
ICCM
LISTED
NASDAQ
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
News Preview
Momentum building in the U.S. and rising interest globally following landmark FDA marketing
authorization for local cryoablation treatment of low-risk breast cancer
Demand for ProSense® systems expected to accelerate in 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
News Preview
This latest approval further broadens global access to ProSense® and supports IceCure's commercial momentum following the U.S. Food and Drug Administration's ("FDA") recent marketing authorization of ProSense® in low-risk breast cancer
CAESAREA, Israel, Nov. 18,...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2025
ICCM
LISTED
NASDAQ
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
News Preview
CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Sto...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ICCM
LISTED
NASDAQ
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
News Preview
CAESAREA, Israel, Nov. 12, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release w...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ICCM
LISTED
NASDAQ
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
News Preview
Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense®
CAESAREA, Israel, Nov. 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM)...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ICCM
LISTED
NASDAQ
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
News Preview
5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone
SBRT followed by cryoablation produced 5-year OS outcomes similar t...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
News Preview
FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Marketing authorization expected to further drive commercial traction based on the high level of interest received at the roundtable event...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
09.10.2025
ICCM
LISTED
NASDAQ
IceCure Medical to Attend the 2025 Maxim Growth Summit
News Preview
IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer
CAESAREA, Israel, Oct. 9, 2025 /PRNewswire/ -- IceCure Med...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
ICCM
LISTED
NASDAQ
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
News Preview
ProSense
® cryoablation offers the choice of
a minimally invasive outpatient procedure that destroys tumors by freezing without surgical remo...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
ICCM
LISTED
NASDAQ
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
News Preview
ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer
Major advancement and new paradigm in...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
News Preview
IceCure's exclusive workshop was filled to capacity – Unlocking De-Escalation of Care: Cryoablation for Breast Cancer led by Key Opinion Leaders Dr. Federica
Di Naro
and Dr. L...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
News Preview
Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis
3 hands-on training sessions for doctors interested in using ProSense® were very well attended
Dedicated CIRSE focus session on the breast shows the growing interest from interventional radiologists to exp...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ICCM
LISTED
NASDAQ
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
News Preview
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience
XSense™ System with Cryoprobes recently received regulatory approval in the U.S. and Israel
CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceC...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ICCM
LISTED
NASDAQ
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
News Preview
Approved for a broad range of indications including in gynecology, oncology and general surgery
CAESAREA, Israel, Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tum...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ICCM
LISTED
NASDAQ
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
News Preview
Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation
Article published in Radiology demonstrated that cryoablation with ProSense® achieved the highest complete ablation rate compared to alternatives with no ad...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
News Preview
Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures
ProSense® is FDA cleared and approved in the European Union for gynecological indications
CAESAREA, Israel, Sept. 4, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "Ice...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2025
ICCM
LISTED
NASDAQ
IceCure Reports Financial & Operational Results for the First Half of 2025
News Preview
$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer
Conference call to be held today at 11:00 am Eastern Time
CAESAREA, Israel, Aug. 13, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCur...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
ICCM
LISTED
NASDAQ
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
News Preview
CAESAREA, Israel, July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the subscription period of its previously announced rights o...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
News Preview
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023
Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence win...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2025
ICCM
LISTED
NASDAQ
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
News Preview
CAESAREA, Israel, July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, reminds rights holders that the subscription period for its previously announced...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
ICCM
LISTED
NASDAQ
IceCure Announces Commencement of Rights Offering
News Preview
CAESAREA, Israel, July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (t...
Themefolio
Profiler
Peergroup
© PR Newswire
03.07.2025
ICCM
LISTED
NASDAQ
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
News Preview
CAESAREA, Israel, July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary financial results as of and for the three and six mont...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
ICCM
LISTED
NASDAQ
IceCure Announces Record Date for Rights Offering for Up to $10 Million
News Preview
CAESAREA, Israel, June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the "Righ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
ICCM
LISTED
NASDAQ
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
News Preview
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer
CAESAREA, Israel, June 9, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
ICCM
LISTED
NASDAQ
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
News Preview
CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operatio...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
ICCM
LISTED
NASDAQ
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
News Preview
Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Papers of 2024" Cryoablation was mentioned favorably during the ASBrS Presidential Address CAESAREA, Israel, May 6, 2025 /PRNewswire/ -- IceCure Medical...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
ICCM
LISTED
NASDAQ
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
News Preview
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study planIceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
ICCM
LISTED
NASDAQ
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
News Preview
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense®IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablationCAESAREA, Israel, April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), develop...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
News Preview
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific sessionIndependent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgeryIn-booth expert exchange session on breast c...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ICCM
LISTED
NASDAQ
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
News Preview
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy
Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024
Conference call to be held today at 10:00 am Eastern Time
CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Lt...
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
ICCM
LISTED
NASDAQ
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
News Preview
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery
CAESAREA, Israel, March 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation te...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
ICCM
LISTED
NASDAQ
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
News Preview
CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operat...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
ICCM
LISTED
NASDAQ
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
News Preview
IceCure working in close collaboration with FDA towards De Novo decision
CAESAREA, Israel, March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
News Preview
IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeonsAn abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation galleryAn independent study by Dr. Ava Kwong evaluated expanding the ICE3 study population to include triple negative breast cancer and you...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ICCM
LISTED
NASDAQ
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
News Preview
This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan
CAESAREA, Israel, March 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
ICCM
LISTED
NASDAQ
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
News Preview
Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
ICCM
LISTED
NASDAQ
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
News Preview
Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand
CAESAREA, Israel, Feb. 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), devel...
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
ICCM
LISTED
NASDAQ
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision
News Preview
Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its categoryHands-on ProSense® training featured during the SIO Mini Masterclass on Breast Cryoablation; the session was extremely well attended with presentations led by interventional oncology and breast canc...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
ICCM
LISTED
NASDAQ
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
News Preview
Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors.FDA decision on market authorization of ProSense® for early-stage breast cancer is expected in the first quarter of 2025.FDA Advisory Panel voted in favor of ProSense®'s benefit-risk profile for early-st...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
ICCM
LISTED
NASDAQ
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
News Preview
CAESAREA, Israel, Jan. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notification letter from Nasdaq Stock Market LLC...
Themefolio
Profiler
Peergroup
© PR Newswire
03.01.2025
ICCM
LISTED
NASDAQ
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
News Preview
XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure
CAESAREA, Israel, Jan. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology t...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
ICCM
LISTED
NASDAQ
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
News Preview
ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth TomkovichFDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025FDA's marketing authorization decision expected in Q1, 2025 CAESAREA, Israel, Dec. 16, 2024 /PRNewswire/ -- IceCure Medical...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ICCM
LISTED
NASDAQ
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
News Preview
Data confirm previous results showing that ProSense® cryoablation is highly effective for kidney tumors < 3 cm and a safe procedure for kidney tumors < 5 cm in people ineligible for surgery Interim results presented at the Israeli Urological Association Conference in Eilat, IsraelProSense® is approved for benign and malignant kidney tumors...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
ICCM
LISTED
NASDAQ
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
News Preview
FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025
Conference call to be held today at 10:00 am Eastern Time
CAESAREA, Israel, Nov. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that d...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
ICCM
LISTED
NASDAQ
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
News Preview
Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablation
CAESAREA, Israel, Nov. 25, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternat...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
ICCM
LISTED
NASDAQ
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
News Preview
CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
ICCM
LISTED
NASDAQ
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
News Preview
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists
PRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with earl...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
ICCM
LISTED
NASDAQ
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
News Preview
FDA decision on marketing authorization expected in the first quarter of 2025
CAESAREA, Israel, Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, anno...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
ICCM
LISTED
NASDAQ
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
News Preview
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA websiteFDA Advisory Panel providing recommendations and vote on information concerning the benefit-risk profile for a De Novo marketing submission of the IceCure ProSense® Cryoablation System in early-stage low risk breast canc...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2024
ICCM
LISTED
NASDAQ
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
News Preview
Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure
CAESAREA, Israel, Oct. 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that d...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ICCM
LISTED
NASDAQ
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
News Preview
ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryoablation, radiofrequency, and microwave) wins EUSOBI Young Physician Scientist Competition – cryoablation demonstrates 94% complete rate of ablation ...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
ICCM
LISTED
NASDAQ
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
News Preview
Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 202496.3% recurrence free rate for women treated with ProSense® cryoablation and endocrine therapy; 100% of patients and treating physicians were satisfied with the cosmetic outcome.Lea...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
ICCM
LISTED
NASDAQ
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
News Preview
Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manageIndependent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense® for indications that are approved in vari...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2024
ICCM
LISTED
NASDAQ
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
News Preview
Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancerFDA decision regarding marketing authorization of ProSense® expected by early 2025CAESAREA, Israel, Sept. 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (N...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
ICCM
LISTED
NASDAQ
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
News Preview
Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming near-term regulatory and operating catalysts
CAESAREA, Israel, Sept. 4, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimal...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
